MedPath

STANDARD CHEM. & PHARM. CO., LTD.

🇹🇼Taiwan
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

2

Active:0
Completed:1

Trial Phases

2 Phases

Phase 1:1
Phase 4:1

Drug Approvals

13

PHILIPPINES:13

Drug Approvals

Adapine S.R.F.C

Approval Date
Jul 14, 2025
PHILIPPINES

Aldocet

Approval Date
Jul 14, 2025
PHILIPPINES

Gastride

Approval Date
Jul 14, 2025
PHILIPPINES

None

Approval Date
Jul 14, 2025
PHILIPPINES

Febustin

Approval Date
Jul 14, 2025
PHILIPPINES

Co-Midis

Approval Date
Jul 14, 2025
PHILIPPINES

Esotan

Approval Date
Jul 14, 2025
PHILIPPINES

Standol

Approval Date
Jul 14, 2025
PHILIPPINES

Febuton

Approval Date
Jul 14, 2025
PHILIPPINES

Dalisoon

Approval Date
Jul 14, 2025
PHILIPPINES
  • Prev
  • 1
  • 2
  • Next

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 1
1 (50.0%)
Phase 4
1 (50.0%)

A Study of Lurasidone HCl in Subjects With Schizophrenia

Phase 4
Completed
Conditions
Schizophrenia
Interventions
First Posted Date
2018-01-08
Last Posted Date
2020-02-05
Lead Sponsor
Standard Chem. & Pharm. Co., Ltd.
Target Recruit Count
54
Registration Number
NCT03393026
Locations
🇨🇳

Taipei City Hospital, Songde Branch, Taipei, Taiwan

🇨🇳

Tri-Service General Hospital, Taipei, Taiwan

Safety, Tolerability and Pharmacokinetics of DCBCI0901 in Patients With Advanced Solid Tumor

Phase 1
Terminated
Conditions
Cancer
Interventions
First Posted Date
2014-05-30
Last Posted Date
2017-10-06
Lead Sponsor
Standard Chem. & Pharm. Co., Ltd.
Target Recruit Count
17
Registration Number
NCT02151357
Locations
🇨🇳

National Cheng Kung University Hospital, Tainan, Taiwan

🇨🇳

National Taiwan University Hospital, Taipei, Taiwan

🇨🇳

Taipei Veterans General Hospital, Taipei, Taiwan

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.